Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cancer drugs targeting signaling pathways have been hampered by problems of efficacy and tumor resistance. Will the next generation of kinase inhibitors fare better than the first? Ken Garber investigates.
Poor national mechanisms for accountability, competition, transparency and ethical oversight allowed Hwang Woo-Suk's descent into ethical, and ultimately scientific, misconduct.
If there's a positive message to take away from the FDA's seemingly endless troubles in 2005, it may be that smaller companies are increasingly registering on the agency's radar.
What appears to be Serono's imminent departure from the ranks of biotech, could be another phase in the maturation of the continent's pharmaceutical sector.